July 1, 2021 -- ERS Genomics Limited announced a nonexclusive license agreement granting Nippon Gene access to its CRISPR-Cas9 patent portfolio.
Nippon Gene is a biotechnology company that manufactures and supplies research reagents across Japan, according to a release. The company's portfolio of reagents for research includes enzymes, buffers and reagents for loop-mediated isothermal amplification (LAMP) and polymerase chain reaction (PCR) kits. Nippon Gene also provides plant disease diagnostic kits, allergen detection kits, and antibiotics detection kits in addition to pregnancy and ovulation tests.
The license allows Nippon Gene to develop, manufacture, and sell research reagents using CRISPR-Cas9 technology.
Financial details of the agreement were not disclosed.
Copyright © 2021 scienceboard.net